SANDOMIGRAN (pizotifen malate)
|
|
- Magdalene Walker
- 6 years ago
- Views:
Transcription
1 SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants. The malate salt is a white to yellow-tinged crystalline powder. MW = , pka 6.95 in water. Excipients: silica colloidal anhydrous, lactose, magnesium stearate, starch-maize, talcpurified, povidone, acacia, sucrose, titanium dioxide, cetyl palmitate. PHARMACOLOGY Pharmacodynamics Sandomigran (pizotifen) is a competitive serotonin antagonist. It also possesses antihistamine, antibradykinin and weak anticholinergic properties. It is suitable for the prophylactic treatment of migraine, reducing the frequency of attacks, but is without effect in the migraine attack. The migraine attack is thought to consist of a prodromal phase of constriction followed by dilatation of the extracranial vessels. The mode of action of pizotifen in preventing migraine is not fully understood but it is known to inhibit the reuptake of serotonin by blood platelets, preventing loss of tone of extracranial vessels. It also possesses appetite-stimulating and antidepressant properties. Pharmacokinetics The absorption of pizotifen is rapid (absorption half-life hours) and nearly complete (estimated 80%). Peak plasma levels are achieved 4-6 hours following a single oral dose. Metabolism is extensive and the drug is widely distributed. Volume of distribution is at least 7 litres/kg. Protein binding amounts to 91%. The main metabolite (N-glucuronide) is eliminated 1
2 with a half-life of about 23 hours. Less than 1% of the drug is excreted in the urine unchanged although as much as 55% of a dose has been detected in the urine as metabolites. In patients with kidney insufficiency dosage adjustment may therefore be necessary. INDICATIONS Prophylactic (interval) treatment of vascular headaches. - typical and atypical migraine - vasomotor headache - cluster headache (Horton's syndrome) Sandomigran is without effect in the migraine attack. For this purpose preparations containing ergotamine are recommended. CONTRAINDICATIONS Hypersensitivity to pizotifen or any of the excipients in the formulation. PRECAUTIONS Renal impairment Caution is required in patients with renal impairment. Dosage adjustment may be necessary. Hepatic impairment Caution is required in patients with hepatic impairment. Dosage adjustment may be necessary. Hepatic injury has been reported, ranging from transaminase elevations to severe hepatitis. Pizotifen treatment should be discontinued if there is any clinical evidence of hepatic dysfunction during treatment and until the cause of the liver abnormality is determined. Withdrawal symptoms Withdrawal symptoms like depression, tremor, nausea, anxiety, malaise, dizziness, sleep disorder and weight decreased have been reported following abrupt cessation of pizotifen (see ADVERSE REACTIONS), therefore gradual withdrawal is recommended. Effects on the ability to drive and use machines: Patients should be warned that Sandomigran may cause sedation, somnolence and dizziness. Therefore, caution should be exercised when driving or using machines. 2
3 Patients being treated with Sandomigran and presenting with sedation and/or somnolence episodes must be instructed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk. Anticholinergic effects: In view of the very slight anticholinergic effect of pizotifen, caution is required in patients with narrow angle glaucoma (except those successfully treated by surgery) or urinary retention (e.g. prostatic enlargement). Up to now no untoward reactions have been reported in such patients given the recommended dosage. Use in Pregnancy (Category B1) No embryotoxic or teratogenic effects were observed in animal studies and fertility was unimpaired. Clinical data with pizotifen in pregnancy are very limited; it should be administered in pregnancy only if the expected benefits outweigh any potential risks. Use in Lactation Animal studies show that pizotifen enters the milk. Although the concentrations of pizotifen measured in the milk of treated mothers are not likely to affect the infant, its use in nursing mothers is not recommended. Use in Children Experience in children is still limited. Interactions with other medicines The following drugs may exhibit drug interactions with pizotifen upon concomitant administration. Anticipated drug interactions to be considered Pizotifen is extensively metabolized in the liver, primarily by N-glucuronidation. Increased plasma concentration of pizotifen upon concomitant administration of drugs which exclusively undergo glucuronidation can not be excluded. Central nervous system agents: Central effects of sedatives, hypnotics, antihistamines, including certain common cold preparations, and alcohol may be enhanced. Monoamine oxidase inhibitors: MAOIs can prolong and intensify the anticholinergic effects of antihistaminic substances. Concomitant use with MAOIs should therefore be avoided. Cisapride: Concomitant administration of pizotifen with cisapride may lead to reduced efficacy of cisapride. 3
4 Epilepsy Seizures as undesirable effects have been observed more frequently in patients with epilepsy. Pizotifen should be used with caution in patients with epilepsy. Sandomigran coated tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption should not take Sandomigran. ADVERSE REACTIONS The most common reactions are appetite-stimulating effect, increase in body weight and sedation (including somnolence and fatigue). It can usually be avoided by increasing the dosage gradually or reversed by a progressive reduction in dosage. The appetite-stimulating effect of pizotifen may lead to an increase in body weight. The following adverse reactions are ranked under headings of frequency; the most frequent first, using the following convention: Very common ( 1/10); common ( 1/100, < 1/10); uncommon ( 1/1000, < 1/100); rare ( 1/10,000, < 1/1000); very rare (< 1/10,000), including isolated reports. Immune system disorders Hypersensitivity reactions, face oedema Metabolism and nutrition disorders Very common: Increased appetite and body weight increased Psychiatric disorders Depression, CNS stimulation (e.g. aggression, agitation), hallucination, insomnia, anxiety Nervous system disorders Common: Sedation (including somnolence), dizziness Paraesthesia Very rare: Seizures Gastrointestinal disorders Common: Nausea, dry mouth Uncommon Constipation Skin and subcutaneous tissue disorders Urticaria, rash Musculoskeletal and connective tissue disorders Myalgia General disorders and administration site conditions Common Fatigue 4
5 Headache, hypotension and impotence have also been reported during treatment with Sandomigran, but a causal relationship was not established. Adverse drug reactions from post-marketing spontaneous reports The following additional adverse drug reactions have been identified with pizotifen based on post-marketing spontaneous reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency. Hepatobiliary disorders Unknown: Hepatic enzyme increased, jaundice, hepatitis Musculoskeletal and connective tissue disorders Unknown: Muscle cramps Withdrawal symptoms Withdrawal reactions have been reported following abrupt cessation of pizotifen, therefore gradual withdrawal is recommended (see PRECAUTIONS). Withdrawal symptoms may include: depression, tremor, nausea, anxiety, malaise, dizziness, sleep disorder and weight decreased. DOSAGE AND ADMINISTRATION The dosage should be progressively increased, starting with 0.5 mg daily. The average maintenance dosage is 1.5 mg daily in single or divided doses. Recent studies have shown a single daily dose of 3 tablets (1.5 mg) taken at night to be effective. In refractory cases the dosage may be gradually raised to mg daily in two or three divided doses. OVERDOSAGE Symptoms Symptoms which may be expected are: drowsiness, nausea, dry mouth, tachycardia, pyrexia, hypotension, dizziness, excitatory states (in children), respiratory depression, convulsions (particularly in children), coma. Treatment Treatment is gastric lavage followed by administration of activated charcoal. If necessary, symptomatic treatment should be given including monitoring of the cardiovascular and respiratory symptoms; for excitatory states or convulsions: benzodiazepines. 5
6 PRESENTATION Tablets containing 0.5 mg pizotifen present as mg pizotifen malate (off-white, sugar-coated); 100's. Store below 30 C. Protect from light. SPONSOR NOVARTIS Pharmaceuticals Australia Pty. Ltd. ABN Waterloo Road, NORTH RYDE, NSW 2113 Approved by the Therapeutic Goods Administration: Date of most recent amendment: 5 May
NEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.
1. PRODUCT NAME ACUPAN 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains nefopam hydrochloride 30 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationSANDOMIGRAN. 0.5mg tablet Pizotifen malate
SANDOMIGRAN 0.5mg tablet Pizotifen malate What is in this leaflet This leaflet answers some common questions about Sandomigran. It does not contain all the available information. It does not take the place
More informationM0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:
M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR:
Core Safety Profile Active substance: Flunarizine Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg P RMS: ES/H/PSUR/0013/001 Date of FAR: 13.12.2010 4.3 Contraindications Flunarizine is
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR:
Core Safety Profile Active substance: Clotiazepam Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg P-RMS: BE/H/PSUR/0002/002 Date of FAR: 16.06.2011 4.3 Contraindications is contraindicated
More informationPRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets
PRODUCT INFORMATION SUDAFED Sinus 12 Hour Relief Tablets NAME OF THE MEDICINE Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 DESCRIPTION SUDAFED Sinus 12 Hour Relief prolonged-release tablets
More informationSanomigran 500 microgram Tablets and Sanomigran 1.5 mg Tablets
Sanomigran 500 microgram Tablets and Sanomigran 1.5 mg Tablets Pizotifen (as malate) Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it
More informationNausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.
Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One orodispersible
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME Sudomyl, Tablet, 60 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Pseudoephedrine Hydrochloride 60mg Excipient(s) with known effect For the full
More informationPRODUCT INFORMATION. (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate
NORGESIC Orphenadrine citrate and paracetamol PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Chemical name: CAS number: 4682-36-4 Chemical structure: Orphenadrine citrate (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine
More informationPRODUCT INFORMATION. AKINETON (biperiden hydrochloride 2 mg tablets)
PRODUCT INFORMATION AKINETON (biperiden hydrochloride 2 mg tablets) NAME OF THE MEDICINE Non-proprietary name: biperiden hydrochloride Structural formula (biperiden): Chemical name (biperiden): α-5-norbornen-2-yl-α-phenyl-1-piperidine
More informationPRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.
PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More information3 PHARMACEUTICAL FORM Coated tablet Round, white to off-white, sugar coated tablets, plain on both sides.
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mebeverine hydrochloride 135 mg coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each coated tablet contains 135 mg of mebeverine
More informationP-RMS: FR/H/PSUR/0036/001
Core Safety Profile Active substance: Alprazolam Pharmaceutical form(s)/strength: Tablet uncoated, sugar coated, film coated, 0.25mg Tablet uncoated, 0.4 mg Tablet uncoated, sugar coated, film coated,
More informationPRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets
PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets NAME OF THE MEDICINE Active Ingredients: Paracetamol and Codeine Phosphate Paracetamol: Molecular Formula: C 8 H
More informationSIBELIUM Capsules Janssen
SIBELIUM Capsules Janssen NAME OF THE MEDICINAL PRODUCT Trade name SIBELIUM International Non-Proprietary Name (Modified) (rinnm) flunarizine hydrochloride QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).
More informationData Sheet. BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other.
BICALOX Data Sheet Bicalutamide 50 mg tablets Presentation BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other. Uses Actions
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fexofenadine hydrochloride 180 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 180mg
More informationMigraleve, Migraleve Pink and Migraleve Yellow Product Information
Migraleve, Migraleve Pink and Migraleve Yellow Product Information Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Unichem Allergy Relief Antihistamine Tablets Moss Pharmacy Allergy Relief Antihistamine Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationNEW ZEALAND DATASHEET
NEW ZEALAND DATASHEET COLDREX HOT REMEDY COLD & FLU HOT LEMON Powder for Oral Solution Paracetamol (BP) 1000mg/sachet Presentation Pale yellow, free flowing heterogeneous powder with and odour of lemon
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationPANADOL SINUS DAY & NIGHT TABLETS PRODUCT INFORMATION
Product description PANADOL SINUS DAY tablet is a white, film-coated capsule-shaped tablet with flat edges, front and back faces marked with DAY. PANADOL SINUS NIGHT tablet is a white, film-coated round
More informationAUSTRALIAN PRODUCT INFORMATION APO-MEBEVERINE. Mebeverine hydrochloride
1 NAME OF THE MEDICINE Mebeverine hydrochloride AUSTRALIAN PRODUCT INFORMATION APO-MEBEVERINE Mebeverine hydrochloride 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each APO-MEBEVERINE tablet contains mebeverine
More informationSIFROL Composition Properties Indication
SIFROL Boehringer Composition 1 tablet contains: 0.125, 0.25 or 1.0 mg, (S)-2- amino-4,5,6,7-tetrahydro-6-propylamino-benzothiazole dihydrochloride monohydrate equivalent to 0.088, 0.18 or 0.7 mg pramipexole
More informationSUMMARY OF PRODUCT CHARACTERISTICS. One film-coated tablet contains 10 mg of cetirizine dihydrochloride.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetirizin STADA 10 mg, film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 10 mg of cetirizine
More informationPRODUCT INFORMATION Panadeine EXTRA
PRODUCT INFORMATION Panadeine EXTRA COMPOSITION Each caplet brand of capsule-shaped tablet contains: Paracetamol 500 mg Codeine phosphate 15 mg and Maize Starch Purified Talc Pregelatinised Maize Starch
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Telfast 120 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 120 mg of fexofenadine hydrochloride,
More informationAUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM
AUSTRALIAN PRODUCT INFORMATION APO-BETAHISTINE (BETAHISTINE DIHYDROCHLORIDE) 1 NAME OF THE MEDICINE Betahistine dihydrochloride. 2 AND 3 QUALITATIVE AND QUANTITATIVE COMPOSITION AND PHARMACEUTICAL FORM
More informationNARAMIG QUALITATIVE AND QUANTITATIVE COMPOSITION
NARAMIG Naratriptan QUALITATIVE AND QUANTITATIVE COMPOSITION Tablets containing 2.5 mg of naratriptan as naratriptan hydrochloride. PHARMACEUTICAL FORM Film coated tablets. CLINICAL PARTICULARS Indications
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fexofenadine Cipla 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg fexofenadine
More informationPANADOL COLD & FLU MAX HOT LEMON Powder for Oral Solution DATA SHEET
PANADOL COLD & FLU MAX HOT LEMON Powder for Oral Solution Paracetamol (BP) 1000mg/sachet DATA SHEET Presentation Pale yellow, free flowing heterogeneous powder with and odour of lemon Indications Fast,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetirizin Mylan 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 10 mg of cetirizine
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1. TRADE NAME OF THE MEDICINAL PRODUCT Mebeverine Tablets BP 135 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 135 mg of Mebeverine Hydrochloride
More informationAVIOMARIN 50 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER AVIOMARIN 50 mg tablets DIMENHYDRINATE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacidipine 2 mg Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg lacidipine. Excipient with known
More informationPanadeine Tablet, Caplets and Rapid Soluble tablets PRODUCT INFORMATION
Panadeine Tablet, Caplets and Rapid Soluble tablets PRODUCT INFORMATION DESCRIPTION Active Ingredients Paracetamol 500 mg Codeine Phosphate 8 mg Excipients Tablets - Starch - maize, talc - purified, stearic
More informationPRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets
PRODUCT INFORMATION Sudafed* Sinus Day + Night Relief Tablets Product description Sudafed* Sinus Day + Night Relief tablets contain two separate formulations: day tablets and night tablets. Each Sudafed*
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT YOCON-GLENWOOD Tablets 5 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 tablet contains 5 mg yohimbine hydrochloride. For a full list of excipients, see section 6.1. 3
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetirizine 10 mg Film-Coated Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 10 mg cetirizine dihydrochloride.
More informationLevocetirizine dihydrochloride
INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate
More informationPRODUCT INFORMATION PANADOL COLD & FLU MAX HOT LEMON POWDER NAME OF THE MEDICINE. Chemical structure: CAS 2 Registry Number: DESCRIPTION
PRODUCT INFORMATION PANADOL COLD & FLU MAX HOT LEMON POWDER NAME OF THE MEDICINE Active ingredient: Paracetamol Chemical structure: CAS 2 Registry Number: 103-90-2 DESCRIPTION Paracetamol is a white, crystalline
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colecalciferol Meda 800 IU tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains colecalciferol (vitamin D 3 ) 800 IU
More informationEmergency contraception is an occasional method. It should in no instance replace a regular contraceptive method.
1. NAME OF THE MEDICINAL PRODUCT: Levonorgestrel Tablets 1.5 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION: Each tablet contains levonorgestrel 1.5 mg. Excipient with known effect: Each tablet contains
More informationPackage Information Leaflet: Information for the user. Calmaben Coated Tablets
Package Information Leaflet: Information for the user Calmaben Coated Tablets Active substance: diphenhydramine hydrochloride Read all of this leaflet carefully before you start taking this medicine because
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Prolonged release tablet 5 mg cetirizine / 120 mg pseudoephedrine. Date of FAR:
Core Safety Profile Active substance: Cetirizine + Pseudoephedrine Pharmaceutical form(s)/strength: Prolonged release tablet 5 mg cetirizine / 120 mg pseudoephedrine P - RMS: BE/H/PSUR/0019/001 Date of
More informationVALERIANA OFFICINALIS 445 MG COATED TABLET Summary of Product Characteristics
Sandoz Business use only Page 1 of 5 Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Valeriaan Sandoz omhulde tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each coated tablet contains
More informationOspolot Sulthiame 50mg and 200mg Tablets
NAME OF THE MEDICINE Sulthiame Sulthiame 50mg and 200mg Tablets Chemical name: 4-(Tetrahydro-2H-1,2-thiazin-2-yl)benzenesulfonamide- S,S-dioxide The molecular weight of the compound is 290.4 and the CAS
More informationTRAPADOL INJECTION FOR I.V./I.M. USE ONLY
TRAPADOL INJECTION FOR I.V./I.M. USE ONLY Composition : Each 2ml. contains : Tramadol Hydrochloride I.P. Water for injection I.P. 100mg. q.s. CLINICAL PHARMACOLOGY : Pharmacodynamics Tramadol is a centrally
More informationCORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013
CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment
More informationSIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product.
SIFROL â Composition 1 tablet contains 0.088, 0.18 & 0.7 mg (S) 2 amino 4,5,6,7-tetrahydro-6-propylamino-benzothiazole (= pramipexole base) equivalent to 0.125, 0.25 & 1 mg of pramipexole dihydrochloride
More informationPANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other.
Product description PANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other. Ingredients Active Ingredients: Paracetamol
More informationPRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets
PRODUCT INFORMATION Sudafed* Sinus Day + Night Relief Tablets Name of the Medicine Paracetamol CAS 2 Registry Number: 103-90-2 Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 Triprolidine
More informationLorazepam Tablets, USP
Lorazepam Tablets, USP DESCRIPTION: Lorazepam, an antianxiety agent, has the chemical formula, 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H -1,4-benzodiazepin-2-one: Cl H N N O Cl OH It is a white
More informationEU Core Safety Profile
EU Core Safety Profile Active Substance: Triazolam Brand Names: HALCION, SOMESE Pharmaceutical form(s)/strength: Tablets RMS: Finland Date: 9 th Dec 2013 Supersedes: 24 th May 2010 4.3. Contraindications
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: ordispersible tablet SE/H/PSUR/0022/002 Date of FAR:
M0BCore Safety Profile Active substance: Zolmitriptan Pharmaceutical form(s)/strength: ordispersible tablet P-RMS: SE/H/PSUR/0022/002 Date of FAR: 15.03.2014 4.3 Contraindications Zolmitriptan is contraindicated
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 100 mg of trimethoprim. For the full list of excipients, see section 6.1.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Trimethoprim 100 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 100 mg of trimethoprim. For the full list
More informationPackage leaflet: Information for the user Zirtek Allergy Relief 10 mg film-coated tablets Cetirizine dihydrochloride
Package leaflet: Information for the user Zirtek Allergy Relief 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:
0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 13.06.2013 4.2 Posology and method of administration
More informationAPPROPRIATE USE GUIDE
APPROPRIATE USE GUIDE PRILIGY is indicated for the treatment of premature ejaculation in adult men aged 18 to 64 years 1 * PRILIGY should only be prescribed to patients who meet all the following criteria:
More informationPharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:
0BCore Safety Profile Active substance: Amisulpride Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: IE/H/PSUR/0017/002 Date of FAR: 28.11.2012 Core Safety Profile [amisulpride] Formulations:
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET VERGO 16 1. Product Name Vergo 16, 16 mg, tablet. 2. Qualitative and Quantitative Composition Each tablet contains 16 mg of betahistine dihydrochloride. For the full list of excipients,
More informationPackage leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride
Package leaflet: Information for the user Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Otrivin Menthol (without preservative) 1.0 mg/ml nasal spray, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 1.0 mg
More informationInformation leaflet for primary care: Agomelatine
Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin
More informationMARKETING AUTHORISATION NO. 403/2007/01-02 Annex 2 Summary of Product Characteristics
Pyrazinamide 500mg tablets ( Antibiotice S. A. ), TB267 WHOPAR part 4 supplier s translation of the text as approved by the stringent regulatory authority June 2014 MARKETING AUTHORISATION NO. 403/2007/01-02
More informationNew Zealand Datasheet. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Bicalutamide 50 mg film coated tablets
New Zealand Datasheet 1 PRODUCT NAME Binarex 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Bicalutamide 50 mg film coated tablets 3 PHARMACEUTICAL FORM Binarex tablets are white to off-white, circular, biconvex,
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Desmopressin acetate 0.2 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 0.2 mg desmopressin acetate tablet corresponds to
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cyklonova 500 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tranexamic acid 500 mg. For the full list of excipients,
More informationPRODUCT INFORMATION. Sudafed* Sinus + Allergy & Pain Relief Tablets
PRODUCT INFORMATION Sudafed* Sinus + Allergy & Pain Relief Tablets Name of the Medicine Paracetamol CAS 2 Registry Number: 103-90-2 Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 Triprolidine
More informationPARACOD Tablets (Paracetamol + Codeine phosphate)
Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s
More informationMolecular formula: Molecular weight: C 8 H 9 NO 2 CAS Registry no.:
Parapane Paracetamol PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Chemical name: Paracetamol N-(4-hydroxyphenyl) Structural formula: Molecular formula: 151.20 Molecular weight: C 8 H 9 NO
More informationNew Zealand Data Sheet
New Zealand Data Sheet 1. PRODUCT NAME Ox-Pam 10mg Tablet Ox-Pam 15mg Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ox-Pam 10mg tablet contains 10mg oxazepam Ox-Pam 15mg tablet contains 15mg oxazepam
More informationNew Zealand Data Sheet
Arrow - Sumatriptan Sumatriptan Injection 6mg/0.5mL Presentation New Zealand Data Sheet ARROW SUMATRIPTAN Injection 6mg/0.5mL is a clear, colourless to pale yellow solution in a prefilled syringe. Uses
More informationCLINICAL PHARMACOLOGY
robaxin / robaxin -7 50 (methocarbamol tablets, USP) Rx Only DESCRIPT ION robaxin /robaxin -750 (methocarbamol tablets, USP), a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant
More informationIMIGRAN. Sumatriptan Tablets. Tablets containing 50mg or 100 mg of sumatriptan base as the succinate salt.
IMIGRAN Sumatriptan Tablets QUALITATIVE AND QUANTITATIVE COMPOSITION Tablets containing 50mg or 100 mg of sumatriptan base as the succinate salt. PHARMACEUTICAL FORM IMIGRAN tablets 50 mg are pink, film-coated,
More informationTranslated from Latvian Approved by SAM on
Translated from Latvian SAM on 29.07.2010 1. NAME OF THE MEDICINAL PRODUCT FENKAROL 10 mg Tablets FENKAROL 25 mg Tablets FENKAROL 50 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance
More informationPackage Leaflet: Information for the user. Anti-Hist Allergy 10mg Film-Coated Tablets. Cetirizine dihydrochloride
Package Leaflet: Information for the user Anti-Hist Allergy 10mg Film-Coated Tablets Cetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains
More informationNEW ZEALAND DATA SHEET. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg cetirizine hydrochloride.
NEW ZEALAND DATA SHEET 1. PRODUCT NAME Zista, 10 mg, tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 10 mg cetirizine hydrochloride. Excipient with known effect: lactose monohydrate
More informationStilnoct 10mg Tablets: White to off-white film-coated oblong tablet, scored and engraved SN 10 on one side, containing 10mg zolpidem tartrate.
1. NAME OF THE MEDICINAL PRODUCT Stilnoct 5mg Stilnoct 10mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Stilnoct 5mg Tablets: Round white film coated tablets containing 5mg zolpidem tartrate. Stilnoct
More informationSummary of Product Characteristics
Summary of Product Characteristics 1. Name of the Medicinal Product Sumatriptan Merck 50 mg film-coated tablet Sumatriptan Merck 100 mg film-coated tablet 2. Qualitative and Quantitative Composition Each
More informationNAME OF THE MEDICINAL PRODUCT IMODIUM CAPS. QUALITATIVE AND QUANTITATIVE COMPOSITION 2 mg loperamide hydrochloride (HCl) per capsule.
NAME OF THE MEDICINAL PRODUCT IMODIUM CAPS QUALITATIVE AND QUANTITATIVE COMPOSITION 2 mg loperamide hydrochloride (HCl) per capsule. PHARMACEUTICAL FORM AND DESCRIPTION Capsules, hard White powder filled
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Atrosan Devil's Claw film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 480 mg of extract
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cyklo-f 500 mg film coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains tranexamic acid 500 mg For the full
More informationSUMMARY OF PRODUCT CHARATERISTICS HYPERIUM. I.N.N. : Rilmenidine
SUMMARY OF PRODUCT CHARATERISTICS HYPERIUM I.N.N. : Rilmenidine 1. DENOMINATION HYPERIUM 1 mg, tablets 2. COMPOSITION Rilmenidine (I.N.N.) dihydrogenphosphate.1.544 mg amount equivalent to rilmenidine
More information(RS)-2-[2-[4-[(4-chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic acid hydrochloride.
Alzene Cetirizine hydrochloride PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Chemical name: cetirizine hydrochloride. (RS)-2-[2-[4-[(4-chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT ALVERINE Mayoly Spindler, 60 mg hard capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 60 mg of alverine citrate.
More information